Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

GlobeNewswireApr 23 20:30

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

GlobeNewswireApr 22 20:30

Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.

Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 2 23:53

HC Wainwright & Co. Maintains Buy on Artelo Biosciences, Maintains $5 Price Target

HC Wainwright & Co. analyst Vernon Bernardino maintains Artelo Biosciences with a Buy and maintains $5 price target.

Analyst UpgradesApr 2 23:42

Artelo Biosciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 233.33% HC Wainwright & Co. $5 → $5 Maintains Buy 11/14/2023 233.33% HC Wainwright & Co. → $5 R

BenzingaApr 2 23:40

Buy Rating on Artelo Biosciences: Strong Pipeline and Market Potential

TipRanksMar 26 18:45